YK-11

YK-11: High-Affinity Myostatin Inhibitor & SARM Hybrid

1. What Is YK-11?

YK-11 is an unusual Selective Androgen Receptor Modulator (SARM) with a backbone closely related to dihydrotestosterone (DHT). Unlike conventional SARMs, YK-11 not only activates androgen receptors in muscle and bone, it also up-regulates follistatin, creating a dual pathway for anabolic activity.

2. How YK-11 Works

1. Selective AR Activation – Targets androgen receptors in skeletal muscle and osteoblasts while sparing reproductive tissues.

2. Myostatin Suppression – Increased follistatin binds and neutralises myostatin, removing a key brake on muscle hypertrophy.

3. Akt/PKB Enhancement – Stimulates protein-kinase B, promoting osteoblast proliferation and higher bone-mineral density.

4. Metabolic Shift – Combines lean-mass gain with accelerated lipolysis, supporting fat-loss objectives.

3. Research-Linked Benefits*

*Findings based on pre-clinical studies; human data are limited.

4. Suggested Research Protocol

• Capsule potency: 5 mg

• Typical range: 5–15 mg once daily

• Cycle length: 4–8 weeks, followed by 2-week off-phase

• Stack options: Frequently combined with MK-2866 (joint support) or GW-501516 (endurance) in investigative settings.

5. Safety & Precautions

Early reports indicate mild testosterone suppression; post-cycle review of hormonal panels is advisable. Possible transient effects include joint tightness or mild aggression at higher doses. Comprehensive human safety data are still forthcoming—limit total cycle duration and monitor liver enzymes and lipids.

Disclaimer
YK-11 is supplied exclusively for laboratory research. It is not approved for human consumption. Handle only in controlled settings and follow all local regulations.